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Abstract
AIM: To investigate endothelin-1 hypo-responsive 
associated with portal hypertension in order to improve 
patient treatment outcomes. 
METHODS: Wild type, eNOS-/- and iNOS-/- mice received 
partial portal vein ligation surgery to induce portal 
hypertension or sham surgery. Development of portal 
hypertension was determined by measuring the splenic 
pulp pressure, abdominal aortic flow and portal systemic 
shunting. To measure splenic pulp pressure, a microtip 
pressure transducer was inserted into the spleen pulp. 
Abdominal aortic flow was measured by placing an 
ultrasonic Doppler flow probe around the abdominal 
aorta between the diaphragm and celiac artery. Portal 
systemic shunting was calculated by injection of 
fluorescent microspheres in to the splenic vein and 
determining the percentage accumulation of spheres in 
liver and pulmonary beds. Endothelin-1 hypo-response 
was evaluated by measuring the change in abdominal 
aortic flow in response to endothelin-1 intravenous 
administration. In addition, thoracic aorta endothelin-1 
contraction was measured in 5 mm isolated thoracic 
aorta rings ex-vivo using an ADI small vessel myograph. 
RESULTS: In wild type and iNOS-/- mice splenic pulp 
pressure increased from 7.5 ± 1.1 mmHg and 7.2 
± 1 mmHg to 25.4 ± 3.1 mmHg and 22 ± 4 mmHg 
respectively. In eNOS-/- mice splenic pulp pressure 
was increased after 1 d (P  = NS), after which it 
decreased and by 7 d was not significantly elevated 
when compared to 7 d sham operated controls (6.9 
± 0.6 mmHg and 7.3 ± 0.8 mmHg respectively, P  = 
0.3). Abdominal aortic flow was increased by 80% 
and 73% in 7 d portal vein ligated wild type and iNOS 
when compared to shams, whereas there was no 
significant difference in 7 d portal vein ligated eNOS-/- 
mice when compared to shams. Endothelin-1 induced 
a rapid reduction in abdominal aortic blood flow in 
wild type, eNOS-/- and iNOS-/- sham mice (50% ± 8%, 
73% ± 9% and 47% ± 9% respectively). Following 
portal vein ligation endothelin-1 reduction in blood 
flow was significantly diminished in each mouse group. 
Abdominal aortic flow was reduced by 19% ± 9%, 
32% ± 10% and 9% ± 9% in wild type, eNOS-/- and 
iNOS-/- mice respectively. 
Basic Study
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CONCLUSION: Aberrant endothelin-1 response in 
murine portal hypertension is NOS isoform independent. 
Moreover, portal hypertension in the portal vein ligation 
model is independent of ET-1 function. 
Key words: Liver disease; Portal hypertension; Hyper-
dynamic circulation; Endothelin-1; Nitric oxide synthase 
isoforms
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Core tip: Portal hypertension (PHT) is a complication 
associated with vascular derangements in response to 
liver disease and fibrosis. Perturbations of nitric oxide 
(NO) and endothelin-1 are believed to be interrelated 
and play a key role in PHT vasculopathy. This study 
investigates the importance of NO biosynthesis in 
endothelin-1 vasoconstriction hypo-response seen 
in patients with PHT. PHT was induced in wild type, 
eNOS-/- and iNOS-/- mice by partial portal vein ligation 
(PVL) and endothelin-1 contractile response was 
determined. Endothelin-1 (ET-1) induced contraction 
was significantly reduced following PVL in all mouse 
groups. Aberrant ET-1 function associated with PHT is 
NO independent. 
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Gastroenterol 2015; 21(16): 4817-4828  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i16/4817.htm  DOI: 
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INTRODUCTION
Portal hypertension (PHT) is a life threatening 
complication of liver cirrhosis. Elevated portal venous 
pressure increases morbidity and mortality by 
promoting the formation and potential hemorrhage 
of gastric and esophageal varices[1,2]. PHT typically 
originates from underlying hepatic disease and is 
exacerbated by systemic and splanchnic vascular 
deregulation[3]. Hepatic injury stimulates liver 
stellate cell differentiation to adopt a smooth muscle 
cell phenotype resulting in sinusoidal contraction, 
increased sinusoidal perfusion resistance and increased 
portal pressure[4]. In addition, dilation of systemic and 
splanchnic vessels causes a hyperdynamic circulatory 
dysfunction characterized by increased cardiac output 
and hyperemia[5-8]. Consequently, although the 
underlying etiology of PHT is usually hepatic, clinical 
manifestations and intervention pertain more to 
vascular and cardiac control[9]. 
Vascular dilators and constrictors play a signi-
ficant role in controlling blood flow and pressure 
via modulation of vascular resistance to flow[10-13]. 
Increased vascular resistance reduces flow and 
increases pressure whereas decreased resistance 
increases flow and lowers pressure. In patients 
with PHT reduced vascular resistance increases blood 
supply to the portal system, which is congested 
because of increased hepatic resistance, and increases 
portal pressure. Consequently, reducing cardiac output 
and increasing vascular resistance has the potential 
to reduce portal pressure and lower the risk of 
esophageal variceal hemorrhage. Primarily prophylaxis 
using β-blockers (e.g., propranolol) to prevent/treat 
variceal bleeding in cirrhotic patients by the reduction 
of heart rate by 25% is the mainstay of treatment 
but does not work for all[14-16]. Moreover, the use of 
vasoconstrictors such as octreotide demonstrate the 
potential for vasoconstrictors despite limited reductions 
in bleeding and no improvement in overall outcomes 
when compared to direct endoscopic treatments to 
the varices (banding and sclerotherapy)[17,18]. The 
introduction of long-acting octreotide analogs may 
provide better results although care should be 
taken to avoid renal complications caused by renal 
hypertension[19,20]. 
Therefore, to date, options for patients with 
PHT, whom are at risk of variceal formation and 
hemorrhage, are limited. One reason for this deficiency 
in treatment options is due to our lack of knowledge 
relating to vascular aberrancies concomitant with 
PHT. Previous studies have demonstrated that PHT is 
associated with a significant diminution of reactivity 
to specific vasoconstrictors[21]. Endothelin-1 (ET1), 
a potent vasoconstrictor, is associated with vascular 
resistance and blood pressure[22]. Previous studies 
indicate that synthesis of the potent vasoconstrictor 
ET1 is increased contemporaneously with PHT[23,24]. 
Plasma ET1 concentrations are three times higher 
in patients with cirrhosis than in healthy controls[25]. 
Subsequent studies showed that despite increased 
ET1 levels vessels from PHT animals exhibited a 
markedly reduced contractile response to exogenous 
ET1[26,27]. In cirrhotic rats mesenteric arterial response 
to endothelin-1 is markedly reduced concomitant with 
a 5-fold reduction in ET1 cellular signaling[28]. This 
reduction in vasoconstrictor response has been linked 
to elevations in expression of vasodilators prostacyclin 
(PGI2) and nitric oxide (NO) which counter ET1 induced 
vasoconstriction[29-32] because disruption of NO or PGI2 
biosynthesis reduces portal pressure in experimental 
models of PHT[33-35]. Suggesting that inhibition of 
vasodilators NO or PGI2 would also ameliorate ET-1 
vasoconstriction in PHT animals. 
Therein this manuscript examines the importance 
and etiology of NO biosynthesis in impaired ET1 
vasoconstriction associated with PHT. This initial study 
utilizes the pre-hepatic murine portal vein ligation (PVL) 
model because PHT develops rapidly and vascular 
aberrancies have been reported in this model[30]. 
At present we do not fully know the importance 
and etiology of ET1 hypo-response in PHT. Previous 
studies have suggested that NO plays a significant 
role in ET1 hypo response[36,37]. This is based on data 
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that shows ET1 hypo-response is not observed when 
NO synthesis is inhibited[38-41] and the connection 
between ET1 signaling, via endothelin receptor A 
(ETA) and endothelin receptor B (ETB) receptors, and 
vasodilatory compounds. (Figure 1)[42] Vascular smooth 
muscle cell ETA and ETB promotes vasoconstriction 
via phospholipase C, phosphoinositide metabolism and 
increased Ca2+[43]. Whereas, endothelial cell ETB are 
functionally coupled with NO and PGI2 biosynthesis 
and promote vasodilation[44-48]. Therefore, increased 
levels of NO biosynthesis via nitric oxide synthase 
isoforms could explain ET1 hypo-contractile response. 
In experimental animal studies ETB antagonism 
prevents hyperemia and PHT following portal vein 
ligation[49]. However, testing the role of ETA and ETB in 
PHT murine models is hindered because, homozygous 
ETA or ETB receptor gene knock out results in lethal 
developmental phenotypes in the mouse[50]. In 
contrast, eNOS-/- and iNOS-/- mice are viable and 
have previously been used to better understand the 
pathophysiology of PHT[34,35]. 
To examine the relationship between eNOS and 
ET-1 hypo-response this manuscript examines the 
development of ET1 hypo response and PHT in a 
murine PVL model of pre-hepatic PHT using eNOS-/- 
mice. If the hypothesis that eNOS is important to the 
development of ET1 hyper-response is correct then 
eNOS gene deletion will prevent aberrant ET1 function 
following PVL. In contrast, we observed that eNOS 
gene deletion enhanced ET1 contraction in sham mice 
and did not prevent ET1 hypo-response following PVL. 
In addition we found that aberrant ET1 contractility 
is not central to the development of PHT in the PVL 
model and that eNOS mediated hyperemia is key. This 
data does not negate the role and importance of ET1 
in portal hypertension. Normalized ET1 contractility, 
potentially, would reduce portal venous flow, pressure 
and bleeding. Our data suggests that targeting of 
NO biosynthesis would not mediate this affect and 
alternate targeting and study is required. 
MATERIALS AND METHODS
Pre-hepatic PHT model: Partial portal vein ligation
All studies were approved by the Indiana University 
committee for animal research and adhered to 
AAALC and federal guidelines for the humane care 
and treatment of animals. Mice were maintained in 
sterilized isolette cages on a 12-h light/dark cycle and 
were allowed access to food and water ad libitum. 
Mice were anesthetized using halothane inhalation. A 
midline laparotomy was performed and the portal vein 
was exposed. A blunt-ended 27-gauge needle was 
placed alongside the portal vein and a 4-0 silk suture 
was tied around the vein and needle, after which 
the needle was withdrawn, producing a standardized 
stenosis. In sham animals the procedure consisted 
of dissection and visual inspection of the portal vein 
without ligature. The abdomen was closed and the 
animals were allowed to recover under a heat lamp. 
Physiological measurements
Physiological measurements were performed as 
previously described by Theodorakis et al[34] 2003. 
At the indicated times post sham-operation or 
PVL, animals were anesthetized and subjected to 
laparotomy to allow physiological measurements to be 
taken. Portal pressure was determined by measuring 
the splenic pulp pressure (SPP). We have previously 
shown that portal venous pressure and splenic pulp 
pressure are directly proportional[34]. To measure 
SPP, a microtip pressure transducer (ADI, CO) was 
inserted into the spleen pulp. Abdominal aortic 
flow (Qao) was measured by placing an ultrasonic 
Doppler flow probe (Transonic #11RB) around the 
abdominal aorta between the diaphragm and celiac 
artery. Flow rates were obtained with a Transonic 
T206 Blood Flow Meter (Transonic Instruments, NY) 
and recorded using ADI Chart 5 software. Aortic 
blood flows were standardized per gram of body 
weight. Fluorescent microspheres were used to assess 
the degree of portosystemic shunting as described 
previously[34]. 0-7 d after sham operation or PVL, mice 
were anesthetized and a laparotomy was performed 
as described earlier. Approximately 15 x 106 μm red 
polystyrene fluorescent microspheres (Molecular 
Probes, Eugene, OR) were injected into the spleen 
(red spheres). The liver and lungs were collected and 
placed in 20 mL of 2% sodium dodecyl sulfate, 0.1 
mol/L EDTA, 10 mmol/L Tris, pH 8.0, and the tissue 
was homogenized. Proteinase K was added to 0.1 
mg/mL, and the proteins were digested overnight at 
45 ℃. Microspheres were collected by centrifugation 
at 1000 × g, washed in 0.2% Tween-80, centrifuged 
again, and re-suspended in 0.1 mL of 0.2% Tween-80. 
Microspheres were counted using a hemocytometer 
and a Nikon TE300 inverted microscope equipped for 
epifluorescence. The degree of shunting was calculated 
as the percentage of microspheres in the lungs 
compared to lung and liver combined.
Gene-deficient mice
Mice containing targeted mutations in the nos2 gene 
(iNOS; strain B6,129P-Nos2tm1Lau,and the nos3 gene 
(eNOS, strain C57BL/6J-Nos3tm1Unc, were purchased from 
The Jackson Laboratory, ME. Age-matched mice from 
congeneic strains (B6, 129P or C57BL/6J) were used 
as wild type controls. Mice genotypes were confirmed 
by PCR on DNA isolated from tail samples using 
Qiagen Dneasy kit (Qiagen Inc, Stamford, CA), as per 
manufactures instructions. Gene-specific primers: nos3: 
5’gtgtgaaggcaaccattctg 3’actcatccatgcacaggacc and 
nos2: 5’ggcttcacgggtcagagcca 3’tgcccattgctgggacagtc 
(cycle = 1 min each of 94 ℃, 60 ℃ and 74 ℃ x 25) are 
complementary to the site specific mutations previously 
published by Shesely et al[51] (1996) and Laubach et 
al[52] (1995).
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L NaHCO3, 1.18 mmol/L KH2PO4, 27 μmol/L EDTA, 
5.5 mmol/L glucose). ET1 contractility was measured 
on a small vessel myograph (610 M, ADI, CO) as per 
manufacturer’s instructions. This instrument provides 
a temperature controlled oxygenated environment 
to measure vessel contractility/dilation. Vessels are 
attached to two wires (0.2 μm diameter). One wire 
is an anchor while the other is attached to a strain 
gauge. Segments were incrementally pre-tensioned by 
separating the two wires to 100 mmHg, as previously 
described and according to manufacturer’s detailed 
instructions[55]. Vessel contractility was measured in 
response to 10-8-10-4 mol/L ET1. Four vessel segments 
were analyzed per mouse, five mice per group. 
Statistical analysis
The data shown are mean ± SE, with 5-7 animals 
per experimental group. Statistical significance was 
estimated using one-way ANOVA statistical analysis. A 
value of p < 0.05 was considered significant.
RESULTS
Plasma NOx
Plasma NOx and ET-1 were determined using 
commercially available assays (Oxford Biomedical, 
Oxford, MI) (R&D systems, Minneapolis, MN). Plasma 
Endothelin-1 function
In-vivo: Seven days Sham and PVL mice were 
anesthetized using halothane inhalation. A midline 
laparotomy was performed and the abdominal aorta 
was exposed. A Doppler flow probe was placed on the 
aorta between the diaphragm and celiac artery. Flow 
rates were allowed to stabilize and were monitored 
while the femoral vein was cannulated. Mice were 
discarded if Qao decreased by more than 20% during 
the cannulation. 10 μg/L (4 nmol/L) ET1 bolus (50 μL) 
was injected in to the femoral vein and the abdominal 
aortic flow was constantly recorded. The dose of ET1 (5 
pmol/kg) was similar to that used in human studies[53]. 
Except ET1 was given as a bolus rather than via a 
peristaltic pump. Preliminary studies showed that 1hr 
following 5 pmol/kg ET1 injection plasma nitrite/nitrate 
(NOx) was increased 41%. Moreover, 4 nmol/L is 
significantly greater than normal murine plasma ET1 
levels (1 pmol/L)[54]. This high dose will equalize out 
any differences in endogenous ET1 levels between PVL 
and sham mice.
Ex-vivo: Seven days Sham and PVL mice were anes-
thetized using halothane inhalation. The abdominal 
aorta was carefully dissected and placed in oxygenated 
Krebs-Ringer solution (119 mmol/L NaCl, 4.7 mmol/L 
KCl, 2.5 mmol/L CaCl, 1.17 mmol/L MgSO4, 25 mmol/
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Figure 1  Illustration of interrelationship between Endothelin-1 induced vasoconstriction and nitric oxide mediated vasodilation. Endothelin-1, PGI2 and NO 
are closely related in relation to vascular smooth muscle cell tone. (Reprinted with permission Ohkita et al[42] 2002).
Theodorakis N et al . ET1 hypo-response in murine pre-hepatic PHT
NOx and ET-1 were not significantly different between 
unadulterated C57B/6J (wild type), iNOS-/- and eNOS-/- 
mice. This is similar to previous studies[34,56]. Plasma 
NOx was increased 1 d following PVL in wild type (41%, 
p = 0.03) and iNOS-/- (35%, p = 0.02) but was not 
altered in eNOS-/- mice (11.7 ± 0.9 vs 9.9 ± 0.6 μmol/L, 
1 d sham and 1 d PVL respectively, p = 0.31). Similarly 
serum ET-1 increased 1 d following PVL (1 ± 0.7 pg/
mL vs 12 ± 3 pg/mL 1 d sham and PVL respectively, p 
= 0.02). After which levels returned to normal (2 ± 1.1 
p = 0.23) and were not different to shams. In a similar 
manner serum ET-1 was increased 9 and 10 fold in 
eNOS-/- and iNOS-/- mice respectively 1 d following PVL. 
Hemodynamics following PVL
The development of PHT was evaluated by recording 
(1) splenic pulp pressure; (2) aortic flow; and (3) 
portal systemic shunting as indices of portal pressure, 
hyperdynamic and collateral circulation respectively. 
Splenic pulp pressure was quantified by placing 
a micro tip pressure transducer into the spleen: 
The spleen/body weight ratio was significantly 
increased in all wild type, iNOS, and eNOS mice 7 d 
following PVL (85%, 90% and 111% respectively). 
In wild type, eNOS-/- and iNOS-/- mice splenic pulp 
pressure was increased immediately following ligation 
of the portal vein. In wild type and iNOS-/- mice splenic 
pulp pressure increased from 7.5 ± 1.1 mmHg and 7.2 
± 1 mmHg to 25.4 ± 3.1 mmHg and 22 ± 4 mmHg 
respectively (Figure 2A and B). In eNOS-/- mice splenic 
pulp pressure was increased after 1 d (p = NS), after 
which it decreased and by 7 d was not significantly 
elevated when compared to 7 d sham operated 
controls (6.9 ± 0.6 mmHg and 7.3 ± 0.8 mmHg 
respectively, p = 0.3) (Figure 2C). This is similar to 
data reported previously[34].
Abdominal aortic flow (Qao) was measured by 
placing a doppler flow probe around the aorta 
between the diaphragm and celiac artery: Heart 
rate was not significantly altered by PVL in any mouse 
groups (data not shown). Immediately after portal 
vein ligation Qao reduced rapidly (0.15 ± 0.02 mL/
min per gram vs 0.12 ± 0.01 mL/min per gram BW 
1 d wild type sham and PVL respectively), decreasing 
by 20%, 22% and 30% in wild type, eNOS-/- and 
iNOS-/- mice respectively. Two days following PVL Qao 
had recovered and was greater in PVL mice when 
compared to shams in wild type and iNOS-/- mice (0.17 
± 0.02 mL/min per gram and 0.18 ± 0.04 mL/min 
per gram BW). By 7 d Qao had increased by 80% and 
73% in wild type and iNOS (Figure 2D and E), whereas 
there was no significant difference in eNOS-/- mice 
between 7 d sham and 7 d PVL (Figure 2F).
Portal systemic shunting was determined by 
injecting fluorescent microspheres in to the 
splenic vein via the spleen and monitoring the 
distribution of spheres between the lung and 
liver: In sham mice spheres were exclusively found 
in the liver, indicating normal circulation and no 
shunting. Following PVL sphere location changed from 
predominantly hepatic to predominantly pulmonary, 
indicative of collateral circulation. The rate of collateral 
circulation development was steady in wild type and 
iNOS-/- mice. (Figure 2G-H) However, in eNOS-/- mice 
the rate of collateralization was significantly slower, 
(Figure 2I) suggesting that acute collateralization is 
eNOS dependent but that alternate mechanisms are 
also involved. 
ET1 induced aortic contractility
To better understand the interrelationship between 
ET1 and NO we initially performed a dose response 
experiment to optimize ET1 induced NO synthesis. This 
would confirm ETB binding and investigates vessel ET1 
pressor response in the face of both constrictive and 
dilatory mechanisms. In-vivo ET1 dose was determined 
by monitoring plasma NOx levels following exogenous 
50 μL bolus (0-20 μg/L) ET1 IV injection. Plasma NOx 
was increased 1hr following 2.5 (23%, p = 0.1) and 5 
pmol/kg (41%, p = 0.04) ET1 IV injection. In contrast, 
IV injection of 10 pmol/kg ET1 reduced NOx 55% 
(p < 0.01). 5 pmol/kg ET1 was subsequently used 
for in-vivo experiments. Aortic response to ET1 was 
determined by (1) in-vivo monitoring of aortic blood 
flow; and (2) ex-vivo monitoring of isolated aorta 
segment contractility. 
Aortic in-vivo response to ET1 was determined 
by monitoring abdominal aortic blood flow 
following IV injection of 50 μl 10 μg/l ET1 via 
the femoral vein: Bolus IV injection of 50 μL 10 μg/L 
(4.8 pmol/kg) ET1 to wild type, eNOS-/- and iNOS-/- 
mice induced a rapid reduction in abdominal aortic 
blood flow (50% ± 8%, 73% ± 9% and 47% ± 9% 
respectively). The ET1 induced reduction in flow was 
significantly greater in eNOS-/- mice compared to both 
wild types and iNOS-/- mice (p = 0.02) (Figure 3A). 7 
d following PVL ET1 induced reduction in blood flow 
was significantly diminished in each mouse group. 
Abdominal aortic flow was reduced by 19% ± 9%, 
32% ± 10% and 9% ± 9% in wild type, eNOS-/- and 
iNOS-/- mice respectively (Figure 3B). Aberrant ET1 
function was significantly greater in iNOS-/- mice (81%) 
when compared to wild type (62%) or eNOS-/- (67%). 
The dose of ET1 is non-physiological and was used 
because it elicited a detectable increase in plasma NOx 
indicative of ET-B activation. Moreover, the dose given 
is equivalent to that used in human studies (4.8 pmol/
kg)[53]. No change in heart rate was observed following 
ET1 injection. 
Vessel ex-vivo response to ET1 was determined 
in isolated abdominal aortic segments attached 
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to a force transducer within an isolated tissue 
bath: Four segments per mouse and 5 mice per 
group were assayed. Vessels were pre- tensioned to 
100 mmHg and equilibrated for 20 min. Vessels were 
exposed to logarithmic increases in ET1 (10-8-10-4 
mol/L). Maximal vessel contractility was recorded. 
Wild type, eNOS-/- and iNOS-/- mouse aortic segments 
increased tension steadily in response to ET1 (Figure 
3C). There was no significant difference between the 
ET1 aortic contractile response of wild type, eNOS 
and iNOS mice at doses between 10-8 and 10-5 mol/L. 
However, at increased doses aortic vessels from 
unadulterated eNOS-.- mice contracted significantly 
greater (43%, p = 0.03) then wild-type controls. 7 
d following PVL contraction to 10-4 mol/L ET1 was 
reduced from 4.2 ± 0.32 to 1.7 ± 0.7 mmol/L in wild 
type mice, 6 ± 0.6 to 1.8 ± 0.1 mmol/L in eNOS-/- 
mice and 4.9 ± 0.7 to 1.5 ± 0.2 mmol/L in iNOS 
mice-/- (Figure 3D).
DISCUSSION
The study described in this manuscript focuses on 
the role of eNOS in ET-1 hypo response associated 
with PHT. Previous reports introduced the hypothesis 
that ET1 hypo-response was linked to NO and/or 
hyperemia[40,49,57]. This study tests this hypothesis 
and the potential of targeting NO biosynthesis to 
reduce portal pressure, variceal formation and 
hemorrhage. This is important because eNOS and 
NO are known to be important to PHT and are the 
basis for intervention in numerous studies[11,58,59]. To 
investigate the role of eNOS in PHT we hypothesized 
that eNOS is important to the development of ET1 
hypo response and that eNOS gene deletion would 
prevent aberrant ET1 function in murine models. The 
hypothesis was challenged using the well-established 
pre-hepatic partial PVL of PHT and targeted eNOS and 
iNOS gene deleted mice. The PVL model was used 
because reduced extra-hepatic arterial ET1 contractile 
response is known to develop rapidly in this model in 
the absence of the milieu of inflammatory and cytokine 
changes associated with the carbon tetrachloride or 
bile duct ligation models of intra-hepatic PHT[60]. This 
allows us to focus on the ET1 vasculopathy in isolation 
from hepatic pathology. iNOS-/- mice were included 
as an isoform and gene deletion control. In both the 
PVL and CCl4 models of PHT iNOS-/- mice develop 
PHT similar to wild type controls, including increased 
plasma NOx, hyperemia, and increased splenic pulp 
pressure. In contrast, eNOS-/- mice didn’t develop 
hyperemia or PHT 7-14 d following PVL. 
In this study we found that eNOS gene deletion 
increased ET1 contractility. This increase in ET1 
contraction in sham eNOS-/- mice is probably due to 
absent eNOS mediated NO biosynthesis and dilation to 
counteract ET1 contraction via ETA receptor activation. 
However, contrary to our hypothesis we observed 
ET1 hypo response in eNOS-/- mice following PVL, 
suggesting that ET1 hypo-response in murine models 
of PHT it is a parallel occurrence rather than a pivotal 
component of PHT and has no distinguishable role 
in hyper-dynamic associated hyperemia. Therefore, 
our hypothesis that eNOS gene deletion would 
prevent aberrant ET1 function was false. At this point 
we suggest that alternative explanations for the 
development of ET1 hypo-response in eNOS-/- mice 
include: (1) reduced blood flow, observed immediately 
following PVL (0-1 d), may increase ET1 expression 
and modify ET1 response. Previous studies have 
shown increased ET1 expression following occlusion 
of portosystemic shunts in cirrhotic patient[61]; (2) 
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Figure 2  Partial portal vein ligation induces chronic hyperemia and persistent portal hypertension in wild type and iNOS-/- mice but not eNOS-/- mice. Wild 
type (a, d, G), iNOS-/- (b, E, h) and eNOS-/- (c, f, I) mice were subjected to partial portal vein ligation surgery. 0-7 d thereafter-splenic pulp pressure (a-c), aortic 
blood flow (d-f) and portal systemic shunting (G-I) were determined. a-c: Splenic pulp pressure was increased acutely in all mouse groups following ligation (0-1 d). 
after which pressure was increased further in wild type and iNOS-/- but not in eNOS-/- mice; d, E: Aortic flow was significantly reduced in wild type, iNOS-/- and eNOS-/- 
mice (0-1 d). In wild type and iNOS-/- mice this low blood flow converted to hyperemia and increased steadily. In eNOS mice flow returned to pre-surgical baseline and 
was not increased; G-I: Portal systemic shunting increased steadily in wild type and iNOS-/- mice (G, h). There was a significant delay in the development of collateral 
circulation in eNOS-/- mice (I). 
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rapid engorgement of the portal vein by PVL activates 
stretch receptors in endothelial cells leading to 
signaling and phenotypic changes[62]; (3) formation 
of free radical and oxidative damage. Cell stretching, 
low blood flow and ET are all linked to the formation 
of oxygen free radicals[63-65]. Free radicals are linked 
to up-regulation of NO, which acts as a superoxide 
radical scavenger, and increases of splanchnic blood 
flow[66-68]. This would explain why ET1 hypo response 
was greater in iNOS-/- mice following PVL as iNOS has 
frequently been linked with NADPH oxidase[69]; (4) 
alternate NOS isoforms may play a key role. Although, 
normally associated with neurons NOS1 or neural NOS 
is increased in the mesenteric artery of PVL rats[70]. 
Addition studies are required to better understand 
the etiology of aberrant ET1 response in PHT; and 
(5) finally, as with all experimental models, especially 
using gene-modified mice, data should be used 
with caution. Firstly, murine models are not 100% 
comparable to human disease. This is especially true 
of the PVL model, which does not mimic the underlying 
causation of the majority of patients with PHT. PVL is 
a model of pre-hepatic PHT, which is usually caused 
by thrombus, or malignancies encroaching upon the 
portal vein. However, the PVL is a “clean” model in 
that it doesn’t include hepatic pathology and allows for 
investigation of PHT vasculopathy in the absence of 
a pro-inflammatory background. Secondly, alternate 
mechanisms can compensate for gene deletion. eNOS 
and iNOS null mice may manifest adaptive effects 
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Figure 3  Endothelin-1 hypo-response develops in wild type, iNOS-/- and eNOS-/- mice following portal vein ligation. A: Aortic blood flow was monitored in 
unadulterated wild type (squares), iNOS-/- (diamonds) and eNOS-/- (triangle) mice prior to and following IV administration of 5 pmol/kg endothelin-1 (ET1). ET1 induced 
a rapid vessel contraction and subsequent reduction in flow. Response to ET1 was significantly greater in eNOS-/- when compared to wild type controls; b: Wild 
type, iNOS-/- and eNOS-/- mice were subjected to sham (open bars) or portal vein ligation surgery (PVL) (shaded bars). After 7 d changes in aortic flow was recorded 
following IV administration of 5 pmol/kg ET1. In all mouse groups the response to ET1 was markedly reduced following PVL (iNOS > wild type > eNOS-/-); c: ET1 
induced contraction of isolated aortic segments from unadulterated wild type (triangle) iNOS-/- (square) and eNOS-/- (triangle) mice were determined using an adI 610M 
small animal myograph. aortic vessel segments contracted to exogenous ET1. at high ET1 dose (10-4 mol/L) aortic vessel segments from eNOS-/- mice contracted 
significantly greater then segments from wild type controls; d: Wild type, iNOS-/- and eNOS-/- mice were subjected to sham (open bars) or portal vein ligation surgery 
(shaded bars). after 7 d the aorta was carefully dissected and ET1 contractility was measured. Ex-vivo aorta ET1 (10-4 mol/L) contractility was significantly decreased 
in vessels from 7 d wild type, iNOS-/- and eNOS-/- PVL mice when compared to shams (PVL vs sham, p < 0.01). 
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such that they may not produce outcomes as a direct 
consequence of a lack of eNOS or iNOS function. An 
alternative to using eNOS-/- mice would be to use 
the reported selective eNOS inhibitor cavtratin, a 
caveolin-1 derived peptide, developed within the Sessa 
laboratory[71,72]. Although, cavtratin is reported to 
inhibit eNOS with little effect on iNOS a question has 
been raised regarding its solubility and applicability 
because of its size (3 kDa)[73]. Finally, we measured 
ET1 response in abdominal aortic vessels rather than 
in mesenteric vessels used in other studies[30]. This 
was because of size restrictions. We were unable to 
isolate responsive mesenteric vessels from either sham 
of PVL mice. However, are able to demonstrate ET1 
hypo-responsive in the abdominal aorta of PVL mice 
when compared to shams. Demonstrating that in PVL 
mice the abdominal aorta reaction to ET1 is reduced in 
a similar manner to mesenteric vessels of PVL rats in 
contrast to increased reaction to ET1 observed in the 
thoracic aorta of PVL rats[30,74].
Ultimately, the data presented in this manuscript 
suggests that targeting eNOS would not abrogate ET1 
hypo-response even though previous studies have 
suggested a link between ET1 and eNOS via ETB. 
This does not refute the positive results seen with ET1 
receptor antagonists. Correcting ET1 function has a 
significant role in the treatment of PHT and prevention 
of variceal formation and hemorrhage. Selective and 
non-selective ET-A and ET-B antagonists have significant 
potential in the treatment of various pathophysiological 
components of PHT[53]. However questions remain 
whether such antagonists should be used clinically to 
treat PHT because of differences between hepatic and 
extra hepatic outcomes. ET1 response is increased in 
the liver but is decreased in the systemic vasculature. 
Moreover, ET-B receptors on vascular smooth muscle 
can contribute to vasoconstriction in some circum-
stances and/or locations. Consequently, alternate 
targets are required that focus on the etiology of ET1 
hypo response and receptor downstream changes. 
However, correcting vascular dysfunction following 
prolonged inflammatory liver disease might be more 
complicated than removing the etiological trigger. Wang 
et al[75] (2004) argue that in patients with chronic portal 
vein hypertension the vascular wall changes, due to 
the long-term dilation, and recovery will be hard even 
if the effect of vasodilatation is completely eliminated. 
More recently, Resch et al[76] have described mesenteric 
arterial remodeling, leading to decreased vessel 
stiffness, in the CCl4 model of PHT. In contrast, they 
found no evidence of vascular remodeling in the rat PVL 
model of PHT, suggesting that irreversible changes are 
more likely a response to an inflammatory milieu and 
not as a consequence of mechanical changes (PVL) or 
increased NO biosynthesis. Because ET1 hypo response 
developed in the absence of an inflammatory response 
and was distant from mechanical/hemodynamic (stretch 
and low flow in the portal vein) changes it is probably 
in response to paracrine signaling. Further studies are 
required to better understand this paracrine signaling. 
In conclusion, ET1 dysfunction occurs in the absence 
of increased NO, chronic liver disease, hyperemia 
or vascular remodeling and is eNOS and iNOS 
independent. Moreover, in the PVL model ET1 hypo-
response is not sufficient, on its own, to induce a 
hyper-dynamic circulation or an increase in portal 
pressure. However, improved ET1 contractility may 
improve clinical options and thus decrease mortality 
and morbidity. Additional studies are required to 
determine the etiology, role and correction of ET1 
hypo-response in PHT. 
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Portal hypertension is a significant complication of liver disease and can 
increase morbidity and mortality. Increased hepatic resistance in portal 
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venous pressure and promotes the vascular aberrancies and hemorrhage. 
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current beta-blocker treatment of patients with portal hypertension is 
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response to vasoconstrictors in patients with portal hypertension would 
significantly improve treatment, morbidity and mortality. 
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by using targeted gene deletion mice this study advances our cognizable 
knowledge of portal hypertension. Previous studies have suggested that hypo-
response to vasoconstrictors is related to an increase in the biosynthesis of 
the vasodilator nitric oxide. arguing that inhibition of nitric oxide synthase will 
ameliorate vascular response to vasoconstrictors. In contrary to this hypothesis 
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is not due to over production of the vasodilator nitric oxide. Targeted gene 
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Terminology
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